Action Silexion Therapeutics - SLXN

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

1,26

Prix Achat

1,25

Prix Vente

1,29

Volume échangé

858 930

1,2206 Fourchette du Jour 1,36

0,575 Plage de 52 semaines 36,36

Clôture Veille

1,37

Ouverture

1,34

Dernière Transaction

1.2895

Dernière heure de transaction

Volume moyen (3 m)

15 529 785

Volume financier

US$ 1 095 536

VWAP

1,2755

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

March 11, 2025 -- InvestorsHub NewsWire -- via Wall Street Wire -- Final Patient Enrolled in Pivotal Phase 3 Trial Following Highly...

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could...

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the...

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave...

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a...

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights...

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the...

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.25	24.7524752475	1.01	1.78	0.98	17526055	1.43875246	CS
4	-0.14	-10	1.4	1.78	0.7358	9945391	1.32008716	CS
12	-2.05	-61.9335347432	3.31	3.45	0.575	15529785	2.07498417	CS
26	-8.19	-86.6666666667	9.45	11.61	0.575	9752399	2.54353592	CS
52	-34.74	-96.5	36	36.36	0.575	8932955	2.95932473	CS
156	-34.74	-96.5	36	36.36	0.575	8932955	2.95932473	CS
260	-34.74	-96.5	36	36.36	0.575	8932955	2.95932473	CS

SLXN - Frequently Asked Questions (FAQ)

What is the current Silexion Therapeutics share price?

The current share price of Silexion Therapeutics is US$ 1,26

What is the 1 year trading range for Silexion Therapeutics share price?

Silexion Therapeutics has traded in the range of US$ 0,575 to US$ 36,36 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
RAYRaytech Holding Ltd	US$ 1,69 (94,25%)	104,03M
TSVT2seventy bio Inc	US$ 4,945 (76,61%)	30,77M
HSAIHesai Group	US$ 24,10 (50,53%)	26,08M
SPHLSpringview Holdings Ltd	US$ 6,00 (47,06%)	1,62M
SYRSSyros Pharmaceuticals Inc	US$ 0,1334 (45,63%)	688,81M
WCTWellchange Holdings Company Limited	US$ 0,68417 (-72,74%)	37,72M
ARVNArvinas Inc	US$ 8,29 (-52,79%)	19,03M
LZMHLZ Technology Holdings Ltd	US$ 8,011 (-48,84%)	685,95k
HTCOHigh Trend International Group	US$ 1,41 (-33,80%)	188,46k
SPGCSacks Parente Golf Inc	US$ 0,1061 (-33,73%)	36,38M
SYRSSyros Pharmaceuticals Inc	US$ 0,1334 (45,63%)	695,66M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0402 (20,00%)	411,84M
NVDANVIDIA Corporation	US$ 108,76 (1,66%)	354,43M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 7,93 (7,45%)	304,67M
CUTRCutera Inc	US$ 0,1079 (-16,03%)	218,46M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Silexion Therapeutics Corporation (SLXN)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

SLXN Dernières nouvelles

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

SLXN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Silexion Therapeutics Corporation (SLXN) Cours

Silexion Therapeutics Corporation (SLXN)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

SLXN Dernières nouvelles

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

SLXN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités